Bone Biologics Corporation
Income Statement
| Line Item | Mar 2021 | Mar 2020 |
|---|---|---|
| Revenue | $1.07B | $1.07B |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $45.5K | $167.1K |
| SG&A Expense | $135.4K | $172.9K |
| Operating Income | $-180.9K | $-340.1K |
| Operating Margin | 0.0% | 0.0% |
| Interest Expense | — | — |
| Pretax Income | $-431.7K | $-595.3K |
| Income Tax Expense | — | $1.6K |
| Net Income | $-431.7K | $-596.9K |
| Net Margin | 0.0% | -0.1% |
| EPS (Basic) | $-0.01 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 87.3M | 920.5M |
| Shares Outstanding (Diluted) | 87.3M | 920.5M |
| Dividends Per Share | — | — |